白云山(600332.SH)：儿童小柴胡颗粒进入II期临床试验

Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (600332.SH) announced that its subsidiary, Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd., has registered the Phase II clinical trial for its pediatric Xiao Chai Hu granules on the National Medical Products Administration's clinical trial registration platform, focusing on the efficacy and safety of the treatment for pediatric gastrointestinal colds [1] Group 1 - The clinical trial is designed as a randomized, double-blind, parallel-controlled, multi-center Phase II study [1] - The study aims to evaluate the effectiveness and safety of pediatric Xiao Chai Hu granules in treating pediatric gastrointestinal colds with Shao Yang syndrome [1]